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ABSTRACT
Background and Aims: Vitamin D deficiency is common among 
patients with inflammatory bowel disease, even when the disease 
is in remission. This study was designed to evaluate the serum 
levels of 25-hydroxy vitamin D [25(OH)-D3] in patients who suffered 
from ulcerative colitis and  the control group in Golestan province 
in the northeast of Iran.
Methods: In this case-control study, 60 patients with a definite 
histopathological diagnosis of ulcerative colitis were included. The 
control group was selected from healthy blood donors. The serum 
levels of 25(OH)-D3 were measured by the ELISA method (ids- UK). 
Data were entered into the SPSS-16 software and were analyzed 
by t-test and Chi-square test.
Results: The mean serum level of vitamin D in the patients was 
significantly lower as compared to that in the control group (P-value 
<0.01). The differences in the levels of 25-OH-D3 were statistically 
significant between the two sexes, in both groups. A normal vitamin 
D level was seen in all cases with proctitis, in 20% of cases in  the 
rectosigmoiditis group and in no cases in the pan-colitis group. The 
difference was statistically significant (p-value <0.01).
Conclusions: It can be concluded that the serum levels of vitamin 
D in the patients with ulcerative colitis are low and that inflammatory 
bowel disease can be a target for the specific vitamin D therapy. 
InTROduCTIOn
Inflammatory Bowel Disease (IBD), which includes Crohn’s Disease 
(CD) and Ulcerative Colitis (UC), is a chronic disease of unknown 
multi-factorial aetiologies. The course of the disease is unpredictable 
and the treatment must focus on the induction and maintenance 
of remission, on preventing complications and on improving and 
preserving the quality of life [1].
Vitamin deficiencies in general and the vitamin D deficiency in 
particular, have been reported in patients with inflammatory bowel 
disease, due to chronic diarrhoea, malabsorption of the nutrients, 
decreased outdoor activities, a short-term high-dose and a long-
term low-dose of prednisone therapy; and it could be common 
even in the remission time of the disease [2-5].
Vitamin D is an important immune system regulator. As there are 
only few foods which contain enough vitamin D, they cannot be 
used as the only sources of this vitamin [6-8]. On the other hand, it 
has been shown that the active form of vitamin D (1, 25-dihydroxy 
vitamin D3) could inhibit the development of autoimmune diseases, 
including Inflammatory Bowel Disease (IBD) and increase bone 
mineralization when it is administered to experimental animals and 
human subjects [6,9]. So, it has not been clearly understood whether 
the vitamin D deficiency plays a role in causing the inflammation 
in the first place or whether it is the result of inflammatory bowel 
disease. This study was designed to evaluate the serum level of 
25-hydroxy vitamin D in patients with ulcerative colitis and in a 
healthy control group in Golestan province, northeast of Iran.
MeThOdS
In this case-control study, 60 patients with ulcerative colitis (N=60) 
and 60 control healthy persons were included. The exclusion criteria 
were as followings: a past history of anti-lipid medicines and a 
history of severe malabsorption diseases, renal disease, and current 
or past corticosteroid consumption. The cases were selected from 
IBD patients who were diagnosed not longer than 6 months prior 
to the study, which were not at the flare-up phase of the disease 
and they were classified as mild to moderate, to decrease the 
effect of the inflammation process on the vitamin level. The control 
group subjects were selected from those healthy blood donors 
who were referred to “Blood Transfusion Organization” in Gorgan 
city (N=60), which were age and sex matched. The individuals with 
gastrointestinal disorders were excluded from the control group. 
This project was approved by the local ethical committee board, 
and it was carried out with the adequate understanding and the 
informed consent of each subject. The serum levels of 25(OH)-D3 
were measured by the ELISA method (ids-UK). Data were entered 
into the SPSS-16 software and analyzed by t-test and Chi-square 
test. All tests were free of charge for cases and controls and this 
was a voluntary decision. 
ReSulTS
The mean serum level of 25(OH)-D3 in the patients (32.03±16.32 
ng/dl) was significantly lower as compared to that in the control 
group (37.78±33.50 ng/dl) (p-value <0.01). The differences in the 
levels of 25(OH)-D3 were statistically significant between the two 
sexes in both groups, i.e. it was lower in women. [Table/Fig-1] It 
was reported that 68% of the men had normal serum levels of 
25(OH)-D3, while only 14.3% of the women had normal serum 
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levels of 25(OH)-D3. The serum levels of 25(OH)-D3 in the patients 
with ulcerative colitis did not show a significant difference regards 
to the age groups, ethnicity and Body Mass Index (BMI). 
All cases in the proctitis group had normal 25(OH)-D3 levels, while 
only 20% of the cases in the rectosigmoiditis group had normal 
levels of vitamin D and in the pan-colitis group, there was no case 
with normal levels of 25(OH)-D3. This difference was statistically 
significant (p-value <0.01). The serum levels of Vitamin D 
were found to be significantly decreased when the disease 
extended into the bowel [Table/Fig-2].
dISCuSSIOn
In the present study, the ulcerative colitis patients had lower serum 
levels of 25(OH)-D3 than the subjects in the control group. In other 
studies, similar results were seen [3-5]. 
It should be noted that vitamin D is absorbed at the end of the 
ileum and that ulcerative colitis does not involve the small bowel 
frequently. By noting the role of vitamin D in the immune system [10] 
and with regards to the fact that the blood samples of the patients 
are taken during the very first months of the diagnosis and before 
the corticosteroids consumption, it could be said that the vitamin D 
deficiency may contribute to the pathogenesis of inflammatory 
bowel disease and that it increases the risk of ulcerative colitis. To 
achieve more accurate results, larger and more precise studies are 
necessary. 
The mean levels of serum 25(OH)-D3 were 54.46 ng/dl, 26.51 ng/
dl and 18.21 ng/dl in the proctitis, the recto-sygmoiditis and the 
pancolitis groups, respectively. Maybe the role of the lower levels 
of vitamin D in the adjustment of the immune system increases 
the intensity and spread of the bowel inflammation, as has been 
emphasized by other studies [9-10], and maybe vitamin D plays a 
role in the pathogenesis of this disease as has been hypothesized 
in the present paper. 
We found that the serum levels of 25(OH)-D3 were higher in males 
than in females, both in the cases and in the control group. This may 
be explained on the basis of the special clothing of the women in 
our country (they wear dark and thick clothes due to their religious 
views) and their relative deprivation of the sun light.
Based on our results, no significant correlation was found between 
the serum levels of 25(OH)-D3 and the ethnicity or the Body Mass 
Index (BMI), which was similar to the findings of others. 
COnCluSIOnS
And finally, it can be concluded that the serum levels of vitamin D 
in the patients with ulcerative colitis is low and that this vitamin may 
play a role in the pathogenesis of this disease; on the other hand, 
inflammatory bowel disease can be a target for the specific vitamin 
D therapy. 
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mean ± Sd(ng/dl)
GroupControls (n = 60) Cases (n = 60)
40.95± 35.99 41.89± 16.26 Male
35.94± 32.32 24.98±12.36 Female
[Table/fig-1]: Serum level of 25-hydroxy vitamin D3 in patients with 
ulcerative colitis and control group regards to the gender.
Mean ± SD (ng/dl) Group
54.46± 11.44 Proctitis
26.51±7.79 Rectosigmoiditis
18.21±5.17 Pancolitis
[Table/fig-2]: Serum level of 25-hydroxy vitamin D3 in patients with 
ulcerative colitis regards to the location of involvement.
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